Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reata Sets Sights On 2012 Bardoxolone Launch With $78 Million Financing In Hand

This article was originally published in The Pink Sheet Daily

Executive Summary

Funding will allow Reata to complete the second of two pivotal trials for its lead product candidate in development for advanced chronic kidney disease.
Advertisement

Related Content

With Generous Partner Abbott Back For More, Reata Aims High Again
Reata Presents Bardoxolone Study Data That Spurred Abbott Deal
Reata Presents Bardoxolone Study Data That Spurred Abbott Deal
Novo Ventures' Hot Streak Of Exits
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug
Abbott Pays $450MM Up-Front For Rights To Reata's CKD Drug
Reata Sells Asian Rights to CKD Drug, But Plans To Remain A Solo Act In U.S.
Reata Sells Asian Rights to CKD Drug, But Plans To Remain A Solo Act In U.S.

Topics

Advertisement
UsernamePublicRestriction

Register

PS070881

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel